216 related articles for article (PubMed ID: 20182311)
1. Meta-analysis of randomized trials: evaluation of benefit of gemcitabine-based molecular targeted therapy for inoperable pancreatic cancer.
Cao Y; Wu L; Tan A; Liu L; Liao C; Gao F
Pancreas; 2010 Mar; 39(2):253-5. PubMed ID: 20182311
[No Abstract] [Full Text] [Related]
2. Gemcitabine doublets in advanced pancreatic cancer: should we move on?
Rocha Lima CM; Flores AM
J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312
[No Abstract] [Full Text] [Related]
3. [Pancreatic carcinoma: progress in therapy].
Lordick F
Krankenpfl J; 2004; 42(5-6):158-9. PubMed ID: 15527223
[No Abstract] [Full Text] [Related]
4. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis.
Tian W; Ding W; Kim S; Xu X; Pan M; Chen S
Pancreatology; 2013; 13(4):415-22. PubMed ID: 23890141
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.
Ottaiano A; Capozzi M; De Divitiis C; De Stefano A; Botti G; Avallone A; Tafuto S
Acta Oncol; 2017 Mar; 56(3):377-383. PubMed ID: 28256961
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
Jin SF; Fan ZK; Pan L; Jin LM
Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.
Heinemann V; Boeck S; Hinke A; Labianca R; Louvet C
BMC Cancer; 2008 Mar; 8():82. PubMed ID: 18373843
[TBL] [Abstract][Full Text] [Related]
8. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).
Di Marco M; Di Cicilia R; Macchini M; Nobili E; Vecchiarelli S; Brandi G; Biasco G
Oncol Rep; 2010 May; 23(5):1183-92. PubMed ID: 20372829
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer.
Chabot JA; Tsai WY; Fine RL; Chen C; Kumah CK; Antman KA; Grann VR
J Clin Oncol; 2010 Apr; 28(12):2058-63. PubMed ID: 19687327
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer.
Yamauchi J; Kanai M; Matsumoto S; Nishimura T; Yazumi S; Kami K; Kawaguchi Y; Yasuda H; Kitano T; Misawa A; Ishiguro H; Yoshikawa K; Yanagihara K; Fukushima M; Doi R; Chiba T
Pancreas; 2008 Apr; 36(3):327-8. PubMed ID: 18362852
[No Abstract] [Full Text] [Related]
12. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
Senderowicz AM; Johnson JR; Sridhara R; Zimmerman P; Justice R; Pazdur R
Oncology (Williston Park); 2007 Dec; 21(14):1696-706; discussion 1706-9, 1712, 1715. PubMed ID: 18247017
[TBL] [Abstract][Full Text] [Related]
13. Front-line therapy of advanced pancreatic cancer.
Kindler HL
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S33-6. PubMed ID: 16399428
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced pancreatic cancer.
Ducreux M; Boige V; Malka D
Semin Oncol; 2007 Apr; 34(2 Suppl 1):S25-30. PubMed ID: 17449349
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine plus cisplatin in advanced pancreatic cancer.
McWilliams RR; Alberts SR
J Clin Oncol; 2007 Mar; 25(9):1142; author reply 1142-3. PubMed ID: 17369580
[No Abstract] [Full Text] [Related]
16. Novel advances in pancreatic cancer treatment.
Vulfovich M; Rocha-Lima C
Expert Rev Anticancer Ther; 2008 Jun; 8(6):993-1002. PubMed ID: 18533808
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.
Xie DR; Liang HL; Wang Y; Guo SS; Yang Q
World J Gastroenterol; 2006 Nov; 12(43):6973-81. PubMed ID: 17109519
[TBL] [Abstract][Full Text] [Related]
18. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Ĺwieboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and platinum combinations in pancreatic cancer.
Philip PA
Cancer; 2002 Aug; 95(4 Suppl):908-11. PubMed ID: 12209670
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.
Wang JP; Wu CY; Yeh YC; Shyr YM; Wu YY; Kuo CY; Hung YP; Chen MH; Lee WP; Luo JC; Chao Y; Li CP
Oncotarget; 2015 Jul; 6(20):18162-73. PubMed ID: 26046796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
